Yadav Krishna, Sharma Mukesh, Nagori Kushagra, Jain Parag, Minz Sunita, Rawat Singh Manju, Singh Deependra, Pradhan Madhulika
Rungta College of Pharmaceutical Sciences and Research, Kohka, Bhilai 490024, India.
Department of Pharmacy, Indira Gandhi National Tribal University, Amarkantak, India.
Curr Drug Deliv. 2025 Apr 3. doi: 10.2174/0115672018350438250311045745.
The global burden of Chronic Liver Diseases (CLDs) is escalating, with increasing prevalence and mortality. Various conditions ranging from fibrosis, cirrhosis, and hepatocellular carcinoma are associated with conditions such as toxin accumulation, viral infections, and metabolic derangements. In this already difficult context, the emergence of metabolic dysfunction-associated steatotic liver disease and steatohepatitis complicated the picture even further. While there has been much advancement in medical research, there is currently no standard cure; hence, the best treatment options are limited, providing a rising need for new therapeutic approaches. Nanoparticle drug delivery systems represent a promising avenue, providing targeted delivery and enhanced therapeutic effectiveness. Nanosystems can protect therapeutic agents from degradation, evade rapid clearance mechanisms, and target drugs directly to a specific hepatic cell type. However, the complex architecture of the liver presents challenges for these therapies, including the need to precisely target individual cells and retain the stability of nanoparticles within the hepatic microenvironment. This review presents recent advances in nanoparticle and targeted ligands-based technologies. These technologies help to navigate barriers associated with similar therapies. As these challenges are addressed, nanotechnological advancements could potentially lead to a major revolution in the treatment of CLDs, paving the way for improved management strategies and providing new hope for affected individuals worldwide.
慢性肝病（CLDs）的全球负担正在不断升级，患病率和死亡率都在上升。从纤维化、肝硬化到肝细胞癌等各种病症都与毒素积累、病毒感染和代谢紊乱等情况相关。在这一已然严峻的背景下，代谢功能障碍相关脂肪性肝病和脂肪性肝炎的出现使情况更加复杂。尽管医学研究已经取得了很大进展，但目前尚无标准的治愈方法；因此，最佳治疗选择有限，对新治疗方法的需求日益增加。纳米颗粒药物递送系统是一条有前景的途径，可实现靶向递送并提高治疗效果。纳米系统可以保护治疗剂不被降解，避开快速清除机制，并将药物直接靶向特定的肝细胞类型。然而，肝脏复杂的结构给这些疗法带来了挑战，包括需要精确靶向单个细胞以及在肝脏微环境中保持纳米颗粒的稳定性。本综述介绍了基于纳米颗粒和靶向配体的技术的最新进展。这些技术有助于克服与类似疗法相关的障碍。随着这些挑战得到解决，纳米技术的进步可能会给慢性肝病的治疗带来重大变革，为改进管理策略铺平道路，并为全球受影响的个体带来新的希望。
